Hormone-Dependent Breast Cancer: Camizestrant Proves Effective Long-Term After Early Mutation Interception

AI justification

Medical breakthrough improves survival in breast cancer via precision oncology. | The study demonstrates a significant medical breakthrough in treating hormone-dependent breast cancer by using circulating tumor DNA to detect ESR1 mutations early, allowing for targeted hormone therapy with camizestrant. This approach improves survival outcomes and aligns with ethical principles of advancing healthcare equity and patient well-being.